“Subcutaneous Treatment for Oncology: Reducing Administration Time and Adverse Effects”

2023-05-30 12:39:16

Oncology
–

Reduces administration time and adverse effects, compared to the intravenous route

The combined combination of subcutaneous pertuzumab and trastuzumab offers better quality of life, without affecting safety and oncological efficacy.

Offering quality of life to patients is another of the objectives of current research. Photo: DM.

1685455904
#subcutaneous #combination #monoclonal #antibodies #lengthens #broadens #quality #life #HER2 #breasts